227 related articles for article (PubMed ID: 17962611)
1. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
4. The histologic spectrum of epithelial neoplasms induced by sorafenib.
Kwon EJ; Kish LS; Jaworsky C
J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
[TBL] [Abstract][Full Text] [Related]
5. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
8. Non-pigmenting fixed drug eruption induced by sorafenib.
Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
[No Abstract] [Full Text] [Related]
9. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
[TBL] [Abstract][Full Text] [Related]
10. Erythema multiforme induced by sorafenib.
Feltes RA; Feito Rodríguez M; González-Beato MJ
Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
[No Abstract] [Full Text] [Related]
11. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
12. Sorafenib: atypical cutaneous side effects.
Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
[No Abstract] [Full Text] [Related]
13. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
14. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
15. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
16. Localized dyskeratotic plaque with milia associated with sorafenib.
Chappell JA; Burkemper NM; Semchyshyn N
J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
19. Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Cicek D; Kandi B; Dagli FA; Karaoglu A; Haligur BD
Clin Drug Investig; 2008; 28(12):803-7. PubMed ID: 18991474
[TBL] [Abstract][Full Text] [Related]
20. Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Sahai S; Swick BL
Int J Dermatol; 2010 Oct; 49(10):1203-6. PubMed ID: 20883411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
